MedTrace Logo

Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants

NCT05599802 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2022-11-01

No results posted yet for this study

Summary

An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010)

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 variant mRNA vaccine low dose

50μg/dose

BIOLOGICAL

SARS-CoV-2 variant mRNA vaccine high dose

100μg/dose

Sponsors & Collaborators

  • Ningbo Rongan Biological Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • LiveRNA Therapeutics Inc.

    collaborator UNKNOWN

  • AIM Vaccine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Prof. Dr. M. Raza Shah · Center for Bioequivalence Studies and Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-05-31
Completion
2024-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05599802 on ClinicalTrials.gov